Understand the source comparison
Best Peptides for Hangover Prevention: Evidence Comparison
NAD+ Precursors (NMN, NR) ALDH2 cofactor replenishment. Supports acetaldehyde clearance 50–250mg subcutaneous Pre-drinking or during consumption 10–15% (precursors only) Moderate. Human trials show reduced acetaldehyde levels but limited hangover symptom data
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- NAD+ Precursors (NMN, NR)
- ALDH2 cofactor replenishment. Supports acetaldehyde clearance
- 50–250mg subcutaneous
- Pre-drinking or during consumption
- 10–15% (precursors only)
- Moderate. Human trials show reduced acetaldehyde levels but limited hangover symptom data
- Reduced L-Glutathione
- Direct ROS neutralization. Prevents lipid peroxidation and DNA damage
- 200–500mg IV or subcutaneous
- 2–4 hours post-drinking (peak oxidative stress window)
- <5%
- Strong. Multiple studies show reduced oxidative markers; limited subjective symptom tracking
- Thymosin Derivatives (Thymalin, TB-500)
- Immune modulation. Downregulates TNF-α, IL-6 inflammatory cytokines
- 5–10mg subcutaneous (Thymalin); 2–5mg (TB-500)
- Post-drinking (inflammatory response phase)
- Negligible
- Preliminary. Animal models show reduced neuroinflammation; human hangover trials absent
- Carnosine (Beta-Alanyl-L-Histidine)
- Acetaldehyde scavenging. Binds acetaldehyde directly to form adducts
- 500–1000mg oral or injectable
- Before and during drinking
- 40–70% (oral carnosine is stable)
- Weak. Mechanistic plausibility high but clinical hangover trials lacking
- Dihexa
- Neuroprotection via BDNF upregulation. Reduces alcohol-induced synaptic damage
- 1–5mg subcutaneous (research dose)
- Pre-drinking (neuroprotective window)
- Unknown (likely <5%)
- Experimental. No hangover-specific trials; neuroprotection data from other contexts
- Professional Assessment
- NAD+ precursors and glutathione have the strongest mechanistic and clinical support for reducing alcohol-induced cellular damage. Thymosin and carnosine show promise but lack robust human trial data for hangover outcomes specifically. Delivery method determines efficacy more than compound selection. Oral protocols fail across all classes except carnosine.